Immuron’s Travelan Trial Published in Scientific Reports Despite Missed Endpoints [VIDEO]
Immuron Travelan Phase 2 results are now peer-reviewed in Nature's Scientific Reports, with a significant 50% cut in ETEC-related adverse events, but the primary efficacy endpoints were still missed.
Key Takeaways
- Immuron's Phase 2 Travelan data is now published in Nature's Scientific Reports, but the results were first released to the ASX on 7 March 2024, so the publication adds credibility rather than new data.
- Travelan delivered a statistically significant 50% reduction in ETEC challenge-related adverse events (P=0.0001), the only result described as statistically significant.
- The trial missed its primary efficacy endpoints, with a placebo attack rate of 33% against an expected 70% cutting statistical power.
- Other endpoints trended in Travelan's favour, including 40% fewer moderate-to-severe cases, 44% fewer cases of all diarrhoea and 71% less early antibiotic use.
- A next-generation delayed-release capsule is built for once-daily dosing, but no larger trial, timeline or funding has been confirmed.
![Syntara Drug Slows Motor Decline in Early Parkinson’s Risk Group, Placebo Worsens [VIDEO]](https://media.stockwirex.com/Glowing-SNT-Letters.jpg)
![Imugene Hires Ex-Allogene Exec as Chief Medical Officer to Drive Azer-Cel Trial [VIDEO]](https://media.stockwirex.com/laboratory-setting.jpg)
![Imugene’s Blood Cancer Drug Hits 71% Response Rate in Hard-to-Treat BTKi Patients [VIDEO]](https://media.stockwirex.com/Lab-with-IMU-sign.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer